12 analysts have shared their evaluations of Intra-Cellular Therapies (NASDAQ:ITCI) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 7 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 3 | 0 | 0 | 0 |
2M Ago | 2 | 3 | 2 | 0 | 0 |
3M Ago | 1 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $102.5, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 3.02% from the previous average price target of $99.50.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent...
Login or create a forever free account to read this news
Sign up/Log in